Categories: NewsPharmaceutical

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference.

Investor Conference Details:

H.C. Wainwright 27th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York City
Conference Dates: September 8-10, 2025
Presentation Date: September 10, 2025 at 10:30 A.M. ET
One on one meeting availability: September 10, 2025

Institutional investors interested in scheduling an in-person one-on-one meeting should contact their institutional sales rep or register for the conference via this LINK.   

A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website at https://pelthos.com. Archived replays will be available for 90 days following the event.

Investor Summit Group Q3 Virtual Conference
Location: Virtual
Conference Dates: September 16-17, 2025

To register for this event please visit this LINK.

About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Pelthos Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072

Staff

Recent Posts

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…

3 hours ago

Cannabix Technologies announces Non-Brokered LIFE Private Placement

  NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

3 hours ago

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often consider…

3 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…

3 hours ago

Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026

A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…

3 hours ago

The UA Sprinkler Fitters Local 669 JATC – Notice of Privacy Incident

Landover, Maryland, February 6, 2026- The UA Sprinkler Fitters Local 669 Joint Apprenticeship and Training…

12 hours ago